KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2016 - 2025)

Regeneron Pharmaceuticals has reported Current Deferred Revenue over the past 17 years, most recently at $553.0 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $553.0 million for Q4 2025, down 11.9% from a year ago — trailing twelve months through Dec 2025 was $553.0 million (down 11.9% YoY), and the annual figure for FY2025 was $553.0 million, down 11.9%.
  • Current Deferred Revenue for Q4 2025 was $553.0 million at Regeneron Pharmaceuticals, up from $545.6 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for REGN hit a ceiling of $627.7 million in Q4 2024 and a floor of $381.1 million in Q2 2023.
  • Median Current Deferred Revenue over the past 5 years was $512.2 million (2021), compared with a mean of $512.9 million.
  • Biggest five-year swings in Current Deferred Revenue: soared 472.54% in 2021 and later crashed 32.7% in 2023.
  • Regeneron Pharmaceuticals' Current Deferred Revenue stood at $442.0 million in 2021, then grew by 8.12% to $477.9 million in 2022, then dropped by 3.98% to $458.9 million in 2023, then soared by 36.78% to $627.7 million in 2024, then dropped by 11.9% to $553.0 million in 2025.
  • The last three reported values for Current Deferred Revenue were $553.0 million (Q4 2025), $545.6 million (Q3 2025), and $481.9 million (Q2 2025) per Business Quant data.